Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Amyloidosis × 30 days × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 64 Ovarian Neoplasms 38 Colorectal Neoplasms 38 Breast Neoplasms 37 Neoplasms 35 Prostatic Neoplasms 30 Neoplasm Metastasis 30 Melanoma 30 Pancreatic Neoplasms 26 Multiple Myeloma 26 Leukemia, Myeloid, Acute 26 Lung Neoplasms 24 Recurrence 21 Endometrial Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 19 Lymphoma, Non-Hodgkin 19 Lymphoma 19 Triple Negative Breast Neoplasms 18 Stomach Neoplasms 17 Myelodysplastic Syndromes 16 Lymphoma, Large B-Cell, Diffuse 16 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Glioblastoma 15 Carcinoma, Renal Cell 15 Uterine Cervical Neoplasms 14 Lymphoma, Follicular 13 Leukemia, Lymphocytic, Chronic, B-Cell 13 Carcinoma, Hepatocellular 12 Small Cell Lung Carcinoma 11 Lymphoma, B-Cell 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07081646 2026-03-13

ALACRITY

Alexion Pharmaceuticals, Inc.

Phase 1/2 Recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡